All In Biotech

Drug Trial Radar · NCT00104260

Study to Evaluate the Response to and Safety of an 8-Day Course of Phenoptin™ Treatment in Subjects With Phenylketonuria

A Phase 2, Multicenter, Open-Label Study to Evaluate the Response to and Safety of an 8-Day Course of Phenoptin™ Treatment in Subjects With Phenylketonuria Who Have Elevated Phenylalanine Levels

Last checked: Nov 20, 2026Latest source record: Apr 9, 2007 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

700

Actual

Start

Dec 2004

Primary completion

Not stated

Study completion Nov 2005

Sponsor

Lead sponsor
BioMarin PharmaceuticalBioMarin (BMRN)
Sponsor type
Industry
First posted
Feb 25, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 8 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective is to evaluate the degree and frequency of response to Phenoptin™ (sapropterin dihydrochloride), as demonstrated by a reduction in blood phenylalanine (Phe) level among subjects with phenylketonuria (PKU) who have elevated Phe levels. A secondary objective of this study is to evaluate the safety of Phenoptin™ treatment in this subject population, and identify individuals in this subject population who respond to Phenoptin™ treatment with a reduction in blood Phe level.

Conditions

  • Phenylketonurias

Interventions

  • sapropterin dihydrochlorideDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the degree and frequency of response to Phenoptin™, as demonstrated by a reduction in blood Phe level among subjects with PKU who have elevated Phe levels

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Los Angeles, California

  • Site not named

    Oakland, California

  • Site not named

    New Haven, Connecticut

  • Site not named

    Chicago, Illinois

  • Site not named

    Boston, Massachusetts

  • Site not named

    Minneapolis, Minnesota

  • Site not named

    St Louis, Missouri

  • Site not named

    New York, New York

  • Site not named

    Portland, Oregon

  • Site not named

    Pittsburgh, Pennsylvania

  • Site not named

    Dallas, Texas

  • Site not named

    Salt Lake City, Utah

  • Site not named

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.